Modulation of immune response and enhanced clearance of Salmonella typhi by delivery of Vi polysaccharide conjugate using PLA nanoparticles

Gonzalez-Fernandez, 2008, Immune responses to polysaccharides: lessons from humans and mice, Vaccine, 26, 292, 10.1016/j.vaccine.2007.11.042 Poolman, 2011, Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines, Expert Rev. Vaccines, 10, 307, 10.1586/erv.11.8 Vakevainen, 2010, Serotype-specific hyporesponsiveness to pneumococcal conjugate vaccine in infants carrying pneumococcus at the time of vaccination, J. Pediatr., 157, 778, 10.1016/j.jpeds.2010.04.071 Dagan, 2010, Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy, J. Infect. Dis., 201, 1570, 10.1086/652006 Astronomo, 2010, Carbohydrate vaccines: developing sweet solutions to sticky situations?, Nat. Rev. Drug Discov., 9, 308, 10.1038/nrd3012 Obukhanych, 2006, T-independent type II immune responses generate memory B cells, J. Exp. Med., 203, 305, 10.1084/jem.20052036 Weintraub, 2003, Immunology of bacterial polysaccharide antigens, Carbohydr. Res., 338, 2539, 10.1016/j.carres.2003.07.008 Guttormsen, 1999, Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines, Infect. Immun., 67, 6375, 10.1128/IAI.67.12.6375-6384.1999 Avci, 2011, A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design, Nat. Med., 17, 1602, 10.1038/nm.2535 Rappuoli, 2018, Glycoconjugate vaccines: Principles and mechanisms, Sci. Transl. Med., 10, 10.1126/scitranslmed.aat4615 Adamo, 2017, Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines, Acc. Chem. Res., 50, 1270, 10.1021/acs.accounts.7b00106 Goldblatt, 2009, The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50–80 years, Clin. Infect. Dis., 49, 1318, 10.1086/606046 Greenberg, 2014, Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age, Vaccine, 32, 2364, 10.1016/j.vaccine.2014.02.002 Musher, 2016, Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant, Hum. Vaccin. Immunother., 12, 331, 10.1080/21645515.2015.1098794 Juergens, 2014, Hum. Vaccin. Immunother., 10, 1343, 10.4161/hv.27998 Flebbe, 1986, Immunopotentiating effects of the adjuvants SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens, Cell. Immunol., 99, 119, 10.1016/0008-8749(86)90221-2 Wuorimaa, 2001, Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers, Pediatr. Infect. Dis. J., 20, 272, 10.1097/00006454-200103000-00011 Haas, 2011, Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens, J. Immunol., 187, 5183, 10.4049/jimmunol.1101990 Souvannavong, 2004, Lipopolysaccharide protects primary B lymphocytes from apoptosis by preventing mitochondrial dysfunction and bax translocation to mitochondria, Infect. Immun., 72, 3260, 10.1128/IAI.72.6.3260-3266.2004 Cirelli, 2019, Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance, Cell, 177, 1153, 10.1016/j.cell.2019.04.012 World Health, O., 2019, Typhoid vaccines: WHO position paper, March 2018 - Recommendations, Vaccine, 37, 214, 10.1016/j.vaccine.2018.04.022 Jiang, 2005, Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens, Adv. Drug Deliv. Rev., 57, 391, 10.1016/j.addr.2004.09.003 Pavot, 2014, Poly(lactic acid) and poly(lactic-co-glycolic acid) particles as versatile carrier platforms for vaccine delivery, Nanomedicine (Lond), 9, 2703, 10.2217/nnm.14.156 Silva, 2016, PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity, Hum. Vaccin. Immunother., 12, 1056, 10.1080/21645515.2015.1117714 Kanchan, 2007, Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response, Biomaterials, 28, 5344, 10.1016/j.biomaterials.2007.08.015 Kanchan, 2009, Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics, Biomaterials, 30, 4763, 10.1016/j.biomaterials.2009.05.075 Anish, 2012, The immunogenic characteristics associated with multivalent display of Vi polysaccharide antigen using biodegradable polymer particles, Biomaterials, 33, 6843, 10.1016/j.biomaterials.2012.06.007 Anish, 2014, Delivery of polysaccharides using polymer particles: implications on size-dependent immunogenicity, opsonophagocytosis, and protective immunity, Mol. Pharm., 11, 922, 10.1021/mp400589q Peres, 2017, Poly(lactic acid)-based particulate systems are promising tools for immune modulation, Acta Biomater., 48, 41, 10.1016/j.actbio.2016.11.012 Micoli, 2011, Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi, Vaccine, 29, 712, 10.1016/j.vaccine.2010.11.022 Micoli, 2012, Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi, Vaccine, 30, 853, 10.1016/j.vaccine.2011.11.108 Panda, 2016, Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles, Pharm. Dev. Technol., 21, 43, 10.3109/10837450.2014.965324 Smith, 1985, Measurement of protein using bicinchoninic acid, Anal. Biochem., 150, 76, 10.1016/0003-2697(85)90442-7 Reddy, 2006, In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles, J. Control. Release, 112, 26, 10.1016/j.jconrel.2006.01.006 Smith, 2014, The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha, Cancer Discov, 4, 1214, 10.1158/2159-8290.CD-13-1007 Link, 2012, Innate immunity mediates follicular transport of particulate but not soluble protein antigen, J. Immunol., 188, 3724, 10.4049/jimmunol.1103312 Rostami, 2017, Co-utilization of a TLR5 agonist and nano-formulation of HIV-1 vaccine candidate leads to increased vaccine immunogenicity and decreased immunogenic dose: A preliminary study, Immunol. Lett., 187, 19, 10.1016/j.imlet.2017.05.002 Reddy, 2007, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol., 25, 1159, 10.1038/nbt1332 Hanson, 2015, Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants, J Clin Invest, 125, 2532, 10.1172/JCI79915 Garg, 2010, Hemoglobin transforms anti-inflammatory Salmonella typhi virulence polysaccharide into a TLR-2 agonist, J. Immunol., 184, 5980, 10.4049/jimmunol.0903512 Kim, 2017, Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity, Biomaterials, 130, 56, 10.1016/j.biomaterials.2017.03.034 Gupta, 2014, Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines, Clin. Vaccine Immunol., 21, 261, 10.1128/CVI.00669-13 Wiedinger, 2017, Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice, Ther. Adv. Vaccines, 5, 15, 10.1177/2051013617691041 Johnson, 2014, Gamma interferon: from antimicrobial activity to immune regulation, Front. Immunol., 5, 667 Kaiko, 2008, Immunological decision-making: how does the immune system decide to mount a helper T-cell response?, Immunology, 123, 326, 10.1111/j.1365-2567.2007.02719.x Begg, 2011, Does a Th1 over Th2 dominancy really exist in the early stages of Mycobacterium avium subspecies paratuberculosis infections?, Immunobiology, 216, 840, 10.1016/j.imbio.2010.12.004 Snapper, 1992, Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens, J. Exp. Med., 175, 1367, 10.1084/jem.175.5.1367 Hussain, 1999, Selective correlation of interferon-gamma, tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor with immunoglobulin G1 and immunoglobulin G3 subclass antibody in leprosy, Immunology, 98, 238, 10.1046/j.1365-2567.1999.00876.x Mawas, 2000, Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model, Vaccine, 19, 1159, 10.1016/S0264-410X(00)00314-5 Jefferis, 1990, Selective IgG subclass deficiency: quantification and clinical relevance, Clin. Exp. Immunol., 81, 357, 10.1111/j.1365-2249.1990.tb05339.x Campbell, 2010, Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity, Clin. Vaccine Immunol., 17, 840, 10.1128/CVI.00529-09 Naess, 1999, Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine, Vaccine, 17, 754, 10.1016/S0264-410X(98)00259-X